Risk of cancers in patients with type 2 diabetes who were treated with DPP-4 inhibitors versus other drugs. DPP4i: dipeptidyl peptidase-4 inhibitors. Subgroup analysis Subgroup analysis was performed to determine whether the type of DPP4i, cancer subtype, drug for comparison, trial duration, or the baseline characteristics (age, HbA1c, BMI, or diabetes duration) had an effect on the RR of ...
Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim ...
bstract Background: Dipeptidyl peptidase 4 (DPP4) plays diverse physiological roles, but its pan-cancer significance and immunomodulatory functions remain poorly characterized. Methods: We performed an integrative pan-cancer analysis of DPP4, incorporating transcriptomic, genomic, and immunogenomic approaches.
Background The use of dipeptidyl peptidase 4 (DPP4) inhibitors in treating type 2 diabetes mellitus (T2DM) is increasingly widespread. However, their association with malignancy risk has not been comprehensively evaluated in real-world clinical settings. This study, utilizing the Food and Drug Adverse Event Reporting System (FAERS) database, investigated the potential link between DPP4 ...
Lee M, Sun J, Han M et al (2019) Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors.
